Ion Beam Applications SA
Marc Leenheer has extensive work experience in the field of project management and leadership. Marc started their career at IBA in 2004 as the VP of Production, where they served for six years. In 2010, they transitioned to the role of Executive Project Director and continued to contribute to the company's success. Marc's valuable expertise led him to become the Project Director at IBA and the co-President of NHa (Normandy Hadrontherapy) in 2019. Their role at IBA & NHa involves overseeing project management and playing a key leadership role.
Marc Leenheer completed their education at ISIB from 1983 to 1987, earning a degree in Industrial Engineering with a focus on Electricity.
This person is not in any teams
Ion Beam Applications SA
4 followers
Ion Beam Applications SA (IBA) is a Belgium-based company that develops and markets technologies, pharmaceutical products and tailored solutions for the healthcare sector, with emphasis on cancer diagnosis and therapy. IBA is also active in the sterilization and ionization field. The Company operates through two business segments, namely the pharmaceuticals segment, which includes radiopharmaceuticals and the equipments segment, which encompasses proton therapy, particle accelerators and dosimetry. Through its various subsidiaries, Ion Beam Applications SA is active in a number of countries, including Belgium, Germany, France, Italy, Spain, the United Kingdom, Sweden, the United States, India and China. In November 2013, the Company announced the closing of the sale of 100% of its business unit Cisbio Bioassays.